企業プロフィール
BridgeBio 株価・ニュース・カタリスト
- ティッカー:
- BBIO
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
81.50 USD (-1.74%)
終値
最終更新: 2026年8月21日
12.5B USD
時価総額
株価変動の要因
The latest monitored company update is “BridgeBio to Present New Acoramidis Data from Open-Label Extension Analyses in ATTR-CM at ESC Congress 2026.” The corresponding closing-price reaction is not yet available.
企業概要
Genetically Defined Diseases
BridgeBio Pharma develops medicines for genetic diseases and genetically driven cancers. Its decentralized portfolio model creates focused teams around individual disease programs.
Attruby
Attruby, or acoramidis, is an oral transthyretin stabilizer approved for transthyretin amyloid cardiomyopathy. It anchors BridgeBio's commercial rare-cardiovascular franchise.
BBP-418
BBP-418 is an oral substrate-supplementation therapy under FDA review for limb-girdle muscular dystrophy type 2I/R9.
Encaleret
Encaleret is an oral calcium-sensing-receptor antagonist being prepared for regulatory submission in autosomal dominant hypocalcemia type 1.
Infigratinib
Low-dose oral infigratinib targets FGFR3 signaling in achondroplasia and is advancing toward an NDA based on late-stage clinical development.
今後のカタリスト
- NDA submission for encaleret in autosomal dominant hypocalcemia type 1 in the first half of 2026.
- NDA submission for oral infigratinib in achondroplasia in the third quarter of 2026.
- FDA review milestones for the submitted BBP-418 application, including a potential Priority Review decision.
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。